Indisulam

Research use only, not for human use.

Indisulam (E7070) is potent, sulfonamide, cell-cycle inhibitor that possesses antiproliferative activities, causes decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines.

Indisulam (E7070) is potent, sulfonamide, cell-cycle inhibitor that possesses antiproliferative activities, causes decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines; causes blockade in the G1/S transition through inhibition of the activation of both cyclin-dependent kinase 2 and cyclin E, shows activity in multiple tumor types, most prominently in colon and lung cancer.Breast Cancer Phase 2 Discontinued(In Vitro):Indisulam (E7070, 0-50 μg/mL, 12-48 h) causes cell cycle perturbation in the G1 phase in a time- and dose-dependent manner, potentially leading to cell death.(In Vivo):Indisulam (E7070, 12.5, 25, 50 (100) mg/kg) shows an antitumour spectrum in human cancer models.

Indisulam (E7070, 0-50 μg/mL, 12-48 h) causes cell cycle perturbation in the G1 phase in a time- and dose-dependent manner, potentially leading to cell death. Cell Cycle Analysis Cell Line:P388 murine leukaemia cells.Concentration:0-50 μg/mL.Incubation Time:12-48 h.Result:Accumulated P388 cells in the G1 phase.

Indisulam (E7070, 12.5, 25, 50 (100) mg/kg) shows an antitumour spectrum in human cancer models. Animal Model:Female BALB/c nu/nu mice aged 7 weeks (HCT116 colon, LX-1 lung, SW620 colon, HCT115 colon, PC-9 lung, DLD-1 colon and WiDr colon models).Dosage:12.5, 25, 50 (100) mg/kg.Administration:IV daily for 4 days.Result:Exhibited anti-tumor activity.

E 7070 | E7070

Cell Cycle/DNA Damage

CDK

carbonicanhydrase|CDK

Cancer

Breast Cancer

165668-41-7

385.85

C14H12ClN3O4S2

>98% (HPLC)

DMSO: 20mg/mL (< 1 mg/ml refers to the product slightly soluble or insoluble)

O=S(C1=CC=C(S(=O)(N)=O)C=C1)(NC2=CC=CC3=C2NC=C3Cl)=O

N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide

(-20℃)

With Ice Pack

≥ 2 years